Skip header and navigation

Refine By

8 records – page 1 of 1.

Association between Ménière's disease and vestibular migraine.

https://arctichealth.org/en/permalink/ahliterature310581
Source
Auris Nasus Larynx. 2019 Oct; 46(5):724-733
Publication Type
Journal Article
Date
Oct-2019
Author
Ilmari Pyykkö
Vinaya Manchaiah
Markus Färkkilä
Erna Kentala
Jing Zou
Author Affiliation
Department of Otolaryngology, Hearing and Balance Research Unit, University of Tampere, Tampere, Finland. Electronic address: http://ilmari.pyykkotuni.fi.
Source
Auris Nasus Larynx. 2019 Oct; 46(5):724-733
Date
Oct-2019
Language
English
Publication Type
Journal Article
Keywords
Adult
Aged
Aged, 80 and over
Anxiety
Female
Finland - epidemiology
Headache - epidemiology - physiopathology
Humans
Logistic Models
Male
Meniere Disease - epidemiology - physiopathology
Middle Aged
Migraine Disorders - epidemiology - physiopathology
Quality of Life
Retrospective Studies
Sense of Coherence
Vertigo - epidemiology - physiopathology
Abstract
The aim of the present study was to evaluate complaints in people with Ménière's disease (MD) with and without migraine and headache to study the association between MD and Vestibular Migraine (VM). We believe this will help us understand if these two disorders represent a disease continuum in that they may share a common aetiology.
The study used a retrospective design and included data of 911 patients with MD from the Finnish Ménière Federation database. The study participants had a mean age of 60.2 years, mean duration of disease of 12.6 years, and 78.7% of the participants were females. The questionnaire data comprised of both disease specific and impact related questions. The data were analyzed using the Mann-Whitney U test, the Kruskal Wallis H test, logistic regression analyses, and decision tree analysis.
Migraine and headache was reported by 190 subjects (20.9%) and 391 subjects (42.9%) respectively. We found that patients that could be classified as VM in the study (i.e., those with frequent vertigo spells associated with migraine) more often reported complaints of severe MD symptoms, had reduced health-related quality of life, suffered more from anxiety, had more neurological complaints, and experienced a reduced sense of coherence than the non-migraneous patients with MD. However, neither the decision tree analysis nor the logistic regression analysis could reliably discriminate VM from MD patients.
Our study results confirm that MD is frequently associated with headache and migraine. In addition, results also indicate that migraine provokes the severity of MD. We suggest that MD and VM may share similar pathophysiological mechanisms. Hence, the future MD classification systems should include a category referred to as 'MD with migraine' that will include patients with VM.
PubMed ID
31054848 View in PubMed
Less detail

Boron neutron capture therapy of brain tumors: clinical trials at the finnish facility using boronophenylalanine.

https://arctichealth.org/en/permalink/ahliterature185360
Source
J Neurooncol. 2003 Mar-Apr;62(1-2):123-34
Publication Type
Article
Author
Heikki Joensuu
Leena Kankaanranta
Tiina Seppälä
Iiro Auterinen
Merja Kallio
Martti Kulvik
Juha Laakso
Jyrki Vähätalo
Mika Kortesniemi
Petri Kotiluoto
Tom Serén
Johanna Karila
Antti Brander
Eija Järviluoma
Päiivi Ryynänen
Anders Paetau
Inkeri Ruokonen
Heikki Minn
Mikko Tenhunen
Juha Jääskeläinen
Markus Färkkilä
Sauli Savolainen
Author Affiliation
Department of Oncology, University of Helsinki, Finland. heikki.joensuu@hus.fi
Source
J Neurooncol. 2003 Mar-Apr;62(1-2):123-34
Language
English
Publication Type
Article
Keywords
Adult
Aged
Boron - blood
Boron Compounds - therapeutic use
Boron Neutron Capture Therapy - adverse effects - instrumentation - mortality
Brain Neoplasms - mortality - radiotherapy
Dose-Response Relationship, Radiation
Female
Finland
Glioblastoma - mortality - radiotherapy
Humans
Male
Middle Aged
Neoplasm Recurrence, Local - radiotherapy
Prospective Studies
Radiotherapy Dosage
Radiotherapy Planning, Computer-Assisted
Survival Rate
Abstract
Two clinical trials are currently running at the Finnish dedicated boron neutron capture therapy (BNCT) facility. Between May 1999 and December 2001, 18 patients with supratentorial glioblastoma were treated with boronophenylalanine (BPA)-based BNCT within a context of a prospective clinical trial (protocol P-01). All patients underwent prior surgery, but none had received conventional radiotherapy or cancer chemotherapy before BNCT. BPA-fructose was given as 2-h infusion at BPA-dosages ranging from 290 to 400 mg/kg prior to neutron beam irradiation, which was given as a single fraction from two fields. The average planning target volume dose ranged from 30 to 61 Gy (W), and the average normal brain dose from 3 to 6 Gy (W). The treatment was generally well tolerated, and none of the patients have died during the first months following BNCT. The estimated 1-year overall survival is 61%. In another trial (protocol P-03), three patients with recurring or progressing glioblastoma following surgery and conventional cranial radiotherapy to 50-60 Gy, were treated with BPA-based BNCT using the BPA dosage of 290 mg/kg. The average planning target dose in these patients was 25-29 Gy (W), and the average whole brain dose 2-3 Gy (W). All three patients tolerated brain reirradiation with BNCT, and none died during the first three months following BNCT. We conclude that BPA-based BNCT has been relatively well tolerated both in previously irradiated and unirradiated glioblastoma patients. Efficacy comparisons with conventional photon radiation are difficult due to patient selection and confounding factors such as other treatments given, but the results support continuation of clinical research on BPA-based BNCT.
PubMed ID
12749708 View in PubMed
Less detail

HHV-6-positivity in diseases with demyelination.

https://arctichealth.org/en/permalink/ahliterature263005
Source
J Clin Virol. 2014 Oct;61(2):216-9
Publication Type
Article
Date
Oct-2014
Author
Jenna Pietiläinen-Nicklén
Jussi O Virtanen
Lasse Uotila
Oili Salonen
Markus Färkkilä
Marjaleena Koskiniemi
Source
J Clin Virol. 2014 Oct;61(2):216-9
Date
Oct-2014
Language
English
Publication Type
Article
Keywords
Adult
Blood - immunology
Cerebrospinal Fluid - immunology
Demyelinating Diseases - etiology - immunology - pathology
Female
Finland
Head - radiography
Herpesvirus 6, Human - immunology
Humans
Magnetic Resonance Imaging
Male
Oligoclonal Bands - cerebrospinal fluid
Roseolovirus Infections - diagnosis - immunology - pathology
Abstract
The triggering agent of multiple sclerosis is still unknown and many viruses, including human herpesvirus-6 (HHV-6), are under suspicion. In earlier study we found patients who had HHV-6 reactive OCBs in their CSF. We wanted to investigate whether HHV-6 has an active role in diseases with demyelination.
To analyze the HHV-6-reactive cases in detail and investigate the possible independent role of HHV-6 in the development of central nervous system involvements with demyelination.
We studied serum and CSF samples that were collected over a period of one year, from all patients who had oligoclonal bands (OCB) in cerebrospinal fluid (CSF) and were examined in the Department of Neurology, University Central Hospital of Helsinki, Finland. Clinical evaluation was accomplished blinded of HHV-6 analysis and follow-up time was two years. All patients underwent MRI of the head and clinically indicated CSF analysis.
The 17 patients with HHV-6-reactive OCBs were significantly younger and had significantly more IgG-OCBs in comparison to patients without HHV-6-reactive OCBs. Initial diagnoses in patients with HHV-6-reactive OCBs remained the same during the follow-up time.
Patients with HHV-6-positive OCBs appear to form a separable group. In progressive neurological diseases HHV-6 may have a role in long-term infection with demyelination.
PubMed ID
25088617 View in PubMed
Less detail

A high-density association screen of 155 ion transport genes for involvement with common migraine.

https://arctichealth.org/en/permalink/ahliterature155857
Source
Hum Mol Genet. 2008 Nov 1;17(21):3318-31
Publication Type
Article
Date
Nov-1-2008
Author
Dale R Nyholt
K Steven LaForge
Mikko Kallela
Kirsi Alakurtti
Verneri Anttila
Markus Färkkilä
Eija Hämaläinen
Jaakko Kaprio
Mari A Kaunisto
Andrew C Heath
Grant W Montgomery
Hartmut Göbel
Unda Todt
Michel D Ferrari
Lenore J Launer
Rune R Frants
Gisela M Terwindt
Boukje de Vries
W M Monique Verschuren
Jan Brand
Tobias Freilinger
Volker Pfaffenrath
Andreas Straube
Dennis G Ballinger
Yiping Zhan
Mark J Daly
David R Cox
Martin Dichgans
Arn M J M van den Maagdenberg
Christian Kubisch
Nicholas G Martin
Maija Wessman
Leena Peltonen
Aarno Palotie
Author Affiliation
Genetic Epidemiology Laboratory, Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Brisbane4029, Queensland, Australia. dale.nyholt@qimr.edu.au
Source
Hum Mol Genet. 2008 Nov 1;17(21):3318-31
Date
Nov-1-2008
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Aged, 80 and over
Case-Control Studies
Child
Demography
European Continental Ancestry Group - genetics
Female
Finland
Gene Frequency
Genes - genetics
Genotype
Humans
Ion Transport - genetics
Male
Middle Aged
Migraine without Aura - genetics
Polymorphism, Single Nucleotide
Young Adult
Abstract
The clinical overlap between monogenic Familial Hemiplegic Migraine (FHM) and common migraine subtypes, and the fact that all three FHM genes are involved in the transport of ions, suggest that ion transport genes may underlie susceptibility to common forms of migraine. To test this leading hypothesis, we examined common variation in 155 ion transport genes using 5257 single nucleotide polymorphisms (SNPs) in a Finnish sample of 841 unrelated migraine with aura cases and 884 unrelated non-migraine controls. The top signals were then tested for replication in four independent migraine case-control samples from the Netherlands, Germany and Australia, totalling 2835 unrelated migraine cases and 2740 unrelated controls. SNPs within 12 genes (KCNB2, KCNQ3, CLIC5, ATP2C2, CACNA1E, CACNB2, KCNE2, KCNK12, KCNK2, KCNS3, SCN5A and SCN9A) with promising nominal association (0.00041
Notes
Cites: Neurology. 2005 Feb 22;64(4):614-2015728281
Cites: Psychol Med. 1997 Nov;27(6):1381-969403910
Cites: Am J Hum Genet. 2005 Sep;77(3):500-1216080125
Cites: Heredity (Edinb). 2005 Sep;95(3):221-716077740
Cites: Hum Mutat. 2005 Oct;26(4):315-2116110494
Cites: Ann Neurol. 2006 Feb;59(2):372-516365871
Cites: Nat Rev Genet. 2006 Oct;7(10):781-9116983374
Cites: Cephalalgia. 2006 Dec;26(12):1462-7217116097
Cites: Curr Opin Neurol. 2007 Jun;20(3):299-30517495624
Cites: Eur J Hum Genet. 2007 Aug;15(8):884-817473835
Cites: Am J Hum Genet. 2007 Sep;81(3):559-7517701901
Cites: Nat Genet. 2007 Sep;39(9):1045-5117728769
Cites: Hum Mol Genet. 2007 Oct 15;16(20):2494-50517666406
Cites: Nature. 2007 Oct 18;449(7164):851-6117943122
Cites: Neurology. 2007 Dec 4;69(23):2170-618056581
Cites: Am J Med Genet B Neuropsychiatr Genet. 2008 Jan 5;147B(1):37-4117680603
Cites: Am J Hum Genet. 2007 Dec;81(6):1278-8317966091
Cites: Hum Biol. 2000 Feb;72(1):35-6210721613
Cites: Neurology. 2000 Sep 12;55(5):624-910980723
Cites: FEBS Lett. 2000 Sep 1;480(2-3):137-4111034315
Cites: Eur J Neurol. 2001 Jan;8(1):61-611509082
Cites: Bioinformatics. 2001 Aug;17(8):742-311524377
Cites: Eur J Neurol. 2001 Sep;8(5):441-911554907
Cites: Twin Res. 2001 Apr;4(2):73-8011665339
Cites: N Engl J Med. 2002 Jan 24;346(4):257-7011807151
Cites: Nat Med. 2002 Feb;8(2):136-4211821897
Cites: Neurology. 1999 Aug 11;53(3):537-4210449117
Cites: J Biol Chem. 1998 Jul 31;273(31):19419-239677360
Cites: Am J Hum Genet. 2002 Mar;70(3):652-6211836652
Cites: Nat Rev Genet. 2005 Feb;6(2):109-1815716907
Cites: Science. 2005 Feb 18;307(5712):1072-915718463
Cites: Brain. 2002 Jun;125(Pt 6):1379-9112023326
Cites: Bioinformatics. 2003 Jan;19(1):149-5012499305
Cites: Nat Genet. 2003 Feb;33(2):192-612539047
Cites: Twin Res. 2002 Oct;5(5):358-6512537859
Cites: Nat Rev Neurosci. 2003 May;4(5):386-9812728266
Cites: Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-512883005
Cites: Am J Hum Genet. 2004 Jan;74(1):106-2014681826
Cites: Ann Neurol. 2004 Feb;55(2):276-8014755732
Cites: Cephalalgia. 2004;24 Suppl 1:9-16014979299
Cites: Genet Epidemiol. 2004 Apr;26(3):231-4415022209
Cites: Am J Hum Genet. 2004 Apr;74(4):765-914997420
Cites: Cephalalgia. 1988;8 Suppl 7:1-963048700
Cites: Control Clin Trials. 1990 Apr;11(2):116-282161310
Cites: Stat Med. 1990 Jul;9(7):811-82218183
Cites: JAMA. 1992 Jan 1;267(1):64-91727198
Cites: Cephalalgia. 1993 Dec;13(6):389-948313452
Cites: Genomics. 1994 Jul 1;22(1):21-67959770
Cites: Am J Hum Genet. 1994 Dec;55(6):1166-727977376
Cites: Cell. 1996 Nov 1;87(3):543-528898206
Cites: Lancet. 2005 Jul 30-Aug 5;366(9483):371-716054936
PubMed ID
18676988 View in PubMed
Less detail

Recurrent lymphocytic meningitis positive for herpes simplex virus type 2.

https://arctichealth.org/en/permalink/ahliterature149544
Source
Emerg Infect Dis. 2009 Jul;15(7):1119-22
Publication Type
Article
Date
Jul-2009
Author
Katariina Kallio-Laine
Mikko Seppänen
Hannu Kautiainen
Marja Liisa Lokki
Maija Lappalainen
Ville Valtonen
Markus Färkkilä
Eija Kalso
Author Affiliation
Helsinki University Central Hospital, Helsinki, Finland. katariina.kallio-laine@helsinki.fi
Source
Emerg Infect Dis. 2009 Jul;15(7):1119-22
Date
Jul-2009
Language
English
Publication Type
Article
Keywords
DNA, Viral - cerebrospinal fluid
Finland - epidemiology
Follow-Up Studies
Herpes Genitalis - complications - epidemiology
Herpesvirus 1, Human - genetics
Herpesvirus 2, Human - genetics - immunology - isolation & purification
Humans
Immunoglobulin G - blood
Lymphocytic Choriomeningitis - cerebrospinal fluid - complications - epidemiology
Recurrence
Time Factors
Abstract
We found the prevalence of recurrent lymphocytic meningitis associated with herpes simplex virus type 2 (HSV-2) was 2.2/100,000 population in Finland during 1996-2006, higher than previous estimates. PCR was most sensitive in detecting HSV-2 DNA from cerebrospinal fluid if the sample was taken 2-5 days after symptom onset.
Notes
Cites: Scand J Infect Dis. 2002;34(4):278-8312064691
Cites: Diagn Cytopathol. 2003 May;28(5):227-3112722116
Cites: J Am Board Fam Pract. 2004 Jul-Aug;17(4):303-515243021
Cites: Lancet. 2004 Aug 7-13;364(9433):501-215302190
Cites: Herpes. 2004 Jun;11 Suppl 2:57A-64A15319091
Cites: Acta Obstet Gynecol Scand. 2004 Oct;83(10):946-915453891
Cites: J Clin Microbiol. 2007 Aug;45(8):2516-2017567785
Cites: Scand J Infect Dis. 1990;22(2):239-402162558
Cites: Genitourin Med. 1994 Dec;70(6):369-777705852
Cites: J Virol Methods. 1996 May;59(1-2):1-118793825
Cites: Acta Neurol Scand. 1998 Sep;98(3):209-129786620
Cites: Epilepsia. 2005 Feb;46(2):327-815679516
Cites: Clin Infect Dis. 2006 Nov 1;43(9):1194-717029141
Cites: South Med J. 1984 Nov;77(11):14766494977
PubMed ID
19624935 View in PubMed
Less detail

A susceptibility locus for migraine with aura, on chromosome 4q24.

https://arctichealth.org/en/permalink/ahliterature191607
Source
Am J Hum Genet. 2002 Mar;70(3):652-62
Publication Type
Article
Date
Mar-2002
Author
Maija Wessman
Mikko Kallela
Mari A Kaunisto
Pia Marttila
Eric Sobel
Jaana Hartiala
Greg Oswell
Suzanne M Leal
Jeanette C Papp
Eija Hämäläinen
Petra Broas
Geoffrey Joslyn
Iiris Hovatta
Tero Hiekkalinna
Jaakko Kaprio
Jürg Ott
Rita M Cantor
John-Anker Zwart
Matti Ilmavirta
Hannele Havanka
Markus Färkkilä
Leena Peltonen
Aarno Palotie
Author Affiliation
Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles 90095-7088, USA.
Source
Am J Hum Genet. 2002 Mar;70(3):652-62
Date
Mar-2002
Language
English
Publication Type
Article
Keywords
Chromosome Mapping
Chromosomes, Human, Pair 4 - genetics
Finland
Genetic Predisposition to Disease
Genome, Human
Humans
Lod Score
Microsatellite Repeats - genetics
Migraine with Aura - genetics
Phenotype
Statistics, nonparametric
Abstract
Migraine is a complex neurovascular disorder with substantial evidence supporting a genetic contribution. Prior attempts to localize susceptibility loci for common forms of migraine have not produced conclusive evidence of linkage or association. To date, no genomewide screen for migraine has been published. We report results from a genomewide screen of 50 multigenerational, clinically well-defined Finnish families showing intergenerational transmission of migraine with aura (MA). The families were screened using 350 polymorphic microsatellite markers, with an average intermarker distance of 11 cM. Significant evidence of linkage was found between the MA phenotype and marker D4S1647 on 4q24. Using parametric two-point linkage analysis and assuming a dominant mode of inheritance, we found for this marker a maximum LOD score of 4.20 under locus homogeneity (P=.000006) or locus heterogeneity (P=.000011). Multipoint parametric (HLOD = 4.45; P=.0000058) and nonparametric (NPL(all) = 3.43; P=.0007) analyses support linkage in this region. Statistically significant linkage was not observed in any other chromosomal region.
Notes
Cites: Neurology. 1998 Sep;51(3):781-69748026
Cites: Ann Neurol. 1999 Feb;45(2):242-69989627
Cites: Neuroreport. 1999 Feb 5;10(2):423-510203347
Cites: Am J Hum Genet. 1999 May;64(5):1453-6310205279
Cites: Neurology. 1999 Sep 22;53(5):995-910496258
Cites: Ann Neurol. 1999 Oct;46(4):606-1110514097
Cites: Am J Hum Genet. 2000 Aug;67(2):282-810884360
Cites: Hum Genet. 2000 Jul;107(1):18-2310982029
Cites: Am J Hum Genet. 1999 Oct;65(4):1060-710486325
Cites: Am J Hum Genet. 1999 Oct;65(4):1114-2410486331
Cites: Neurogenetics. 2000 Sep;3(1):35-4011085595
Cites: Am J Med Genet. 2000 Dec 4;96(6):762-411121176
Cites: Nat Rev Genet. 2000 Dec;1(3):182-9011252747
Cites: Cephalalgia. 2000 Dec;20(10):900-611304025
Cites: Neurology. 2001 Apr 24;56(8):1028-3211320173
Cites: Nat Genet. 2001 May;28(1):87-9111326283
Cites: Neurology. 2001 May 22;56(10):1273-711376172
Cites: N Engl J Med. 2001 Jul 5;345(1):17-2411439943
Cites: Eur J Neurol. 2001 Jan;8(1):61-611509082
Cites: Headache. 2001 Jul-Aug;41(7):646-5711554952
Cites: Ann Hum Genet. 1983 Oct;47(Pt 4):311-206651220
Cites: Am J Hum Genet. 1984 Mar;36(2):460-56585139
Cites: Cephalalgia. 1988;8 Suppl 7:1-963048700
Cites: JAMA. 1992 Jan 1;267(1):64-91727198
Cites: Hum Hered. 1992;42(1):77-921555848
Cites: Cephalalgia. 1992 Aug;12(4):221-8; discussion 1861525797
Cites: Cephalalgia. 1992 Aug;12(4):229-37; discussion 1861525798
Cites: Cephalalgia. 1992 Dec;12(6):383-4; discussion 3401341430
Cites: Cephalalgia. 1993 Aug;13(4):245-88374938
Cites: Nat Genet. 1993 Sep;5(1):40-58220421
Cites: J Med Genet. 1993 Oct;30(10):857-658230163
Cites: Cephalalgia. 1993 Dec;13(6):389-948313452
Cites: Science. 1994 Sep 30;265(5181):2037-488091226
Cites: Headache. 1994 Jun;34(6):319-287928310
Cites: Genomics. 1994 Oct;23(3):707-97851903
Cites: Int J Epidemiol. 1994 Oct;23(5):1020-67860153
Cites: Headache. 1995 Feb;35(2):70-87737864
Cites: Ann Hum Genet. 1995 Jan;59(Pt 1):83-957762986
Cites: BMJ. 1995 Aug 26;311(7004):541-47663209
Cites: Cephalalgia. 1995 Jun;15(3):200-47553809
Cites: Nat Genet. 1995 Nov;11(3):241-77581446
Cites: Hum Genet. 1995 Nov;96(5):604-88530012
Cites: Headache. 1995 Oct;35(9):513-98530274
Cites: Hum Genet. 1995 Dec;96(6):726-308522335
Cites: Am J Hum Genet. 1996 Jun;58(6):1323-378651310
Cites: Am J Hum Genet. 1996 Jun;58(6):1347-638651312
Cites: Nat Genet. 1996 Sep;14(1):90-48782826
Cites: Cephalalgia. 1996 Jun;16(4):239-458792035
Cites: Cell. 1996 Nov 1;87(3):543-528898206
Cites: Cephalalgia. 1997 Jun;17(4):488-91; discussion 4879209767
Cites: Neurology. 1997 Jul;49(1):201-69222191
Cites: Am J Hum Genet. 2000 Apr;66(4):1298-30910731467
Cites: Am J Hum Genet. 2000 Apr;66(4):1310-2710731466
Cites: Hum Mol Genet. 2000 Apr 12;9(7):1049-5710767329
Cites: Science. 2000 Apr 28;288(5466):678-8210784452
Cites: Headache. 1997 Sep;37(8):479-859329229
Cites: Hum Mol Genet. 1997 Oct;6(11):1973-89302278
Cites: Neurology. 1997 Nov;49(5):1231-89371899
Cites: Ann Neurol. 1997 Dec;42(6):885-909403481
Cites: Hum Mol Genet. 1998 Mar;7(3):459-639467004
Cites: Am J Hum Genet. 1997 Dec;61(6):1379-879399895
Cites: Neurology. 1998 May;50(5):1428-329596000
Cites: Cephalalgia. 1998 Jan;18(1):23-69601620
Cites: Am J Hum Genet. 1998 Jul;63(1):259-669634505
Cites: Headache. 1998 Jun;38(6):417-229664744
Cites: Am J Hum Genet. 1998 Sep;63(3):861-99718341
Cites: Cephalalgia. 1998 Jul-Aug;18(6):329-329731937
PubMed ID
11836652 View in PubMed
Less detail

8 records – page 1 of 1.